Onkologie. 2024:18(1):59-62 | DOI: 10.36290/xon.2024.012
Dostarlimab in the 1st line treatment of metastatic and recurrent endometrial cancer
- Klinika onkologie a radioterapie, FN Hradec Králové
Metastatic endometrial cancer still represents a major medical and social problem, and patients and their doctors have so far faced a very unfavorable prognosis of the disease and little chance of inducing long-term remission. For many decades, palliative treatment was based mainly on chemotherapy or hormone therapy, and research into targeted therapy or modern cytostatic therapy did not yield satisfactory results. Thanks to better molecular-genetic knowledge, we can better categorize endometrial tumors and better predict the treatment response to chemotherapy and especially to the increasingly rapidly developing immunotherapy targeting the PD-1 receptor and its ligands. This work aims to present the PD-1 inhibitor dostarlimab (JEMPERLI) and its unprecedentedly significant contribution to treating patients with this malignancy.
Keywords: dostarlimab, endometrial carcinoma, immunotherapy, PD-1.
Accepted: February 22, 2024; Published: February 28, 2024 Show citation
References
- Mitric C, Bernardini MQ. Endometrial Cancer: Transitioning from Histology to Genomics. Curr Oncol. 2022;29(2): 741-757.
Go to original source... 
Go to PubMed... - Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26): 2509-2520. Go to original source... Go to PubMed...
- Lorenzi M, Amonkar M, Zhang J, et al. Epidemiology of Microsatellite Instability High (MSI-H) and Deficient Mismatch Repair (dMMR) in Solid Tumors: A Structured Literature Review. J Oncol. 2020;2020. Go to original source...
- Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: Results from the phase II KEYNOTE-158 study. J Clin Oncol. 2020;38(1): 1-10. Go to original source... Go to PubMed...
- Markham A. Dostarlimab: First Approval. Drugs. 2021;81(10):1213-1219. Go to original source... Go to PubMed...
- Oaknin A, Gilbert L, Tinker AV, et al. Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: Interim results from GARNET - A phase I, single-arm study. J Immunother Cancer. 2022;10(1). Go to original source... Go to PubMed...
- Pothuri B, Gilbert L, Sabatier R, et al. Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study. Clin Cancer Res. 2023;29(22):4564-4574. Go to original source... Go to PubMed...
- Mirza MR, Chase DM, Slomovitz BM, et al. Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer. N Engl J Med. 2023;388(23):2145-2158. Go to original source... Go to PubMed...